Background Disease-specific studies have reported impaired humoral responses after
SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated with …

Background Data are scarce on immunogenicity of COVID-19 vaccines in patients with
autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to …

June 18, 2021 https://doi. org/10.1016/S2665-9913 (21) 00181-8 digital platforms has had
an adverse impact on diversity and participation from under-represented groups due to …

Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …

Background: Patients affected by different types of autoimmune diseases, including common
conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated …

Background Studies have suggested incremental short-term adverse events (AE) after
repeated vaccination. In this report, we assessed occurrence and risk factors for short-term AEs …

Objectives To evaluate whether a third vaccination shows an added effect on severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple …

For patients with immune-mediated inflammatory diseases (IMIDs), concerns exist about
increased disease activity after vaccination. We aimed to assess changes in disease activity …

Background Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants
(ISPs) may have impaired long-term humoral immune responses and increased …

Objectives To compare the cumulative incidence and disease severity of reported SARS-CoV-2
omicron breakthrough infections between patients with immune-mediated inflammatory …